Stockscreener 앱 받기
2.23
0.45%
0.010
전일 마감가:
$2.22
열려 있는:
$2.22
하루 거래량:
1.27M
Relative Volume:
0.73
시가총액:
$216.12M
수익:
$20.76M
순이익/손실:
$-132.49M
주가수익비율:
-0.8352
EPS:
-2.67
순현금흐름:
$-108.55M
1주 성능:
+4.21%
1개월 성능:
-1.33%
6개월 성능:
+10.40%
1년 성능:
-42.23%
1일 변동 폭
$2.165
$2.29
1주일 범위
$2.02
$2.47
52주 변동 폭
$1.085
$4.025
C 4 Therapeutics Inc Stock (CCCC) Company Profile
명칭
C 4 Therapeutics Inc
전화
(617) 231-0700
주소
490 ARSENAL WAY, WATERTOWN
CCCC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.23 | 215.15M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 개시 | TD Cowen | Buy |
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-15 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2024-12-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 개시 | Stephens | Equal-Weight |
| 2024-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-12-13 | 업그레이드 | Stifel | Hold → Buy |
| 2023-02-24 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-04-28 | 개시 | Credit Suisse | Underperform |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-10 | 개시 | JP Morgan | Overweight |
| 2022-02-11 | 재개 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-11-23 | 개시 | BofA Securities | Buy |
| 2021-10-14 | 개시 | SVB Leerink | Mkt Perform |
| 2021-09-30 | 개시 | Stifel | Hold |
| 2021-06-04 | 개시 | H.C. Wainwright | Buy |
| 2021-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-27 | 개시 | BMO Capital Markets | Outperform |
| 2020-10-27 | 개시 | Jefferies | Buy |
모두보기
C 4 Therapeutics Inc 주식(CCCC)의 최신 뉴스
C4 Therapeutics’ chief medical officer Reyno sells $22,200 in stock - Investing.com
Insider Sell: Leonard Reyno Sells Shares of C4 Therapeutics Inc (CCCC) - GuruFocus
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - PharmiWeb.com
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Aug Intraday: Is Coincheck Group NV stock good for income investorsJuly 2025 Big Picture & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
C4 Therapeutics’ Phase 2 Myeloma Trial Moves Forward, Setting Up a Key Catalyst for CCCC Investors - TipRanks
C4 Therapeutics to advance cemsidomide trials for multiple myeloma By Investing.com - Investing.com Nigeria
C4 Therapeutics (CCCC) Announces Ambitious Milestones Through 20 - GuruFocus
C4 Therapeutics to advance cemsidomide trials for multiple myeloma - Investing.com
C4 Therapeutics Outlines Strategic Milestones for Cemsidomide - TradingView — Track All Markets
C4 Therapeutics Advances Cemsidomide Trials and Internal Discovery Strategy Ahead of Key Milestones Through 2028 - Quiver Quantitative
Potential multiple myeloma drug from C4 Therapeutics plans trials to 2028 - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
C4 Therapeutics Sets Up New Combination Trial in Multiple Myeloma: What Investors Should Watch - TipRanks
How C4 Therapeutics Inc. stock performs in weak economy - Улправда
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
Is C4 Therapeutics Inc. stock trading at a premium valuationWeekly Trend Recap & Smart Swing Trading Techniques - Улправда
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PharmiWeb.com
Is C4 Therapeutics Inc. stock in correction or buying zoneJuly 2025 Big Picture & Safe Swing Trade Setups - Улправда
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Is C4 Therapeutics Inc. stock oversold or undervaluedMarket Growth Review & Accurate Entry/Exit Alerts - Улправда
How C4 Therapeutics Inc. stock benefits from tech adoptionQuarterly Market Summary & Free Weekly Chart Analysis and Trade Guides - ulpravda.ru
Is C4 Therapeutics (CCCC) one of the best biotech penny stocks to buy according to analysts? - MSN
Market Rankings: Is C4 Therapeutics Inc stock oversold or undervaluedQuarterly Portfolio Review & Breakout Confirmation Alerts - moha.gov.vn
C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
C4 Therapeutics, Inc.Common Stock (NQ: CCCC - FinancialContent
Brookline Capital Management Estimates C4 Therapeutics FY2030 Earnings - MarketBeat
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Fate Therapeutics reports new employee inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Karyopharm Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 31, 2025 - BioSpace
Sarepta Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Is C4 Therapeutics (CCCC) One of the Best Biotech Penny Stocks to Buy According to Analysts? - Insider Monkey
Abeona Therapeutics® announces new employee inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
C4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Significant Growth in Short Interest - MarketBeat
C 4 Therapeutics Inc (CCCC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):